Northwest Biotherapeutics, Inc.

NWBO

US66737P6007

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 20:59:22 16/07/2024 BST			5-day change	1st Jan Change
0.395 ^USD	+1.19%		-1.99%	-43.65%

06-29	Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call
05-10	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Northwest Biotherapeutics: 3Q Earnings Snapshot

January 15, 2021 at 12:42 pm

BETHESDA, Md. (AP) _ Northwest Biotherapeutics Inc. (NWBO) on Friday reported a loss of $194.1 million in its third quarter.

The Bethesda, Maryland-based company said it had a loss of 26 cents per share. Losses, adjusted for non-recurring costs and to extinguish debt, were 7 cents per share.

The cancer drug developer posted revenue of $216,000 in the period.

The company's shares closed at $1.32. A year ago, they were trading at 21 cents.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NWBO at https://www.zacks.com/ap/NWBO

Latest news about Northwest Biotherapeutics, Inc.

Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	06-29
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors	03-21	CI
Northwest Biotherapeutics, Inc. Announces Retirement of Jerry Jasinowski from the Board of Directors	03-14	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05	CI
Northwest Biotherapeutics Announces Marketing Authorization Application Has Been Submitted to the UK MHRA for DCVax-L for Glioblastoma	12-21	CI
Northwest Biotherapeutics, Inc. announced that it has received $11.005 million in funding from Streeterville Capital, LLC	11-09	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Northwest Biotherapeutics Appoints Linda Liau to its Scientific Advisory Board	12/09/23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	28/02/23	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	27/02/23	CI
Transcript : Northwest Biotherapeutics, Inc. - Shareholder/Analyst Call	30/12/22
Northwest Biotherapeutics Sues Citadel Securities, Other Market Market Makers for Alleged Stock Price Manipulation	01/12/22	MT
Northwest Biotherapeutics Reports Positive Top-Line Results from Phase 3 Trial of DCVax®-L for Glioblastoma	17/11/22	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/11/22	CI
Northwest Biotherapeutics Files $250 Million Mixed Shelf	19/10/22	MT
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan by MHRA	23/08/22	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	09/08/22	CI
Northwest Biotherapeutics Announces Filing of Application for License for Commercial Manufacturing At Sawston, Uk Facility	06/07/22	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	10/05/22	CI
Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	01/03/22	CI
Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	28/02/22	CI
Northwest Biotherapeutics Announces Commencement of Cancer Vaccine Production At Its Sawston, UK Facility	17/02/22	CI

Chart Northwest Biotherapeutics, Inc.

Duration

Period

More charts

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Companyâs wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
NORTHWEST BIOTHERAPEUTICS, INC.	-43.65%	481M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B